Any indication that results are positive will see Sarepta jump on ANP to compliment their existing DMD drug Eteplirsen which only work with 13% of DMD patients. ATL1102 can be used to reduce inflammation in all DMD patients and for other conditions... we should also be expecting to hear soon about the Phase 11b European trial for ATL1102 which will be run in parallel and the ATL1103 EAP. Plenty of announcements about to drop..
DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-63
-
- There are more pages in this discussion • 240 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $35.58K | 335.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 555558 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 41673 | 2 |
View Market Depth
| Last trade - 11.01am 18/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |